多病共存时代临床试验的再思考:以患者为中心的定制化方法势在必行
该评论性文章指出,多病共存影响约40%的成年人和超过一半的60岁以上成年人,传统试验设计难以应对其复杂性,降低结果的外推性。文章基于德国Bielefeld国际专题研讨会见解,倡导采用适应性设计、预设亚组分析及患者报告结局等以患者为中心的整合性试验方法,并呼吁制定针对多病共存试验的SPIRIT扩展报告规范。
要点
- 多病共存影响约40%成人及超半数60岁以上人群,传统试验设计常不适用。
- 推荐采用适应性设计、预设亚组分析及患者报告结局与体验测量。
- 呼吁制定针对多病共存试验的SPIRIT扩展报告规范以指导方案适配。
核心结论
- 需要转向更整体和整合的实验方法,以患者为中心设计多病共存临床试验,弥合研究与实践的差距。
研究设计与样本
- 评论性文章,基于德国Bielefeld国际专题研讨会的见解,综述针对或涉及多病共存患者的试验现状。
主要发现
- 多病共存影响约40%的成年人和超过一半的60岁以上成年人。
- 传统试验设计无法充分考虑干预的背景及多种健康状况的相互作用,降低结果的外推性和适用性。
关键数值与推荐
- 倡导适应性试验设计、预设亚组分析,以及纳入患者报告结局和体验测量(如照护负担)。
- 呼吁制定针对多病共存试验的特定报告指南,如SPIRIT扩展。
临床怎么用
- 在试验设计中采用适应性设计和预设亚组分析,以适配多病共存患者的异质性。
- 纳入患者报告结局与体验测量,确保研究反映患者、照护者及临床医生的需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Multimorbidity, the coexistence of two or more chronic conditions, affects about 40% of all adults and over half of adults over 60 years. The complexity of multimorbidity (MM) often renders traditional trial designs inadequate, unable to account for the context of interventions, including the interplay of multiple health conditions in daily life. This gap reduces the generalizability and applicability of their results. METHODS: This commentary aims to review the current state of trials targeting or involving patients with MM. Highlighting current limitations and drawing on insights from an international dedicated workshop in Bielefeld, Germany, we identify an ongoing and pressing need for innovative, patient-centered approaches to their design and conduct. RESULTS: We propose a shift toward more holistic and integrative experimental approaches, including developing interventions tailored to the characteristics and needs of patients with MM, establishing relevant outcomes, and enhancing data collection and process evaluation. We specifically advocate for adaptive trial designs, prespecified subgroup analyses, and the incorporation of patient-reported outcomes and experience measures such as burden of care to ensure that research is both comprehensive and reflective of the needs of patients living with MM, their caregivers, and of the clinicians participating in their care. Ethical considerations are discussed in our commentary as well, emphasizing the importance of patient safety, data protection, and informed consent. Finally, we call for the development of specific reporting guidance, such as a SPIRIT extension tailored to MM trials, to help researchers adapt standard protocols to the complex and heterogeneous reality of this population. CONCLUSION: This commentary aims to bridge the gap between research and practice, fostering the development of effective interventions that improve patient outcomes and enhance the quality of care for patients living with MM.
引用
- González-González AI, Fabbri E, Schürmann L, et al. Rethinking clinical trials in the multimorbidity era: the imperative for patient-centered tailored approaches. J Clin Epidemiol. 2026. PMID: 41765346. doi:10.1016/j.jclinepi.2026.112204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。